GT Biopharma | 10-Q: FY2025 Q3 Revenue: USD 0

Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

The global cancer therapy market is projected to grow from $244 billion in 2025 to $404 billion by 2030, driven by advancements in targeted cell therapies and precision degraders. GT Biopharma, Inc. has successfully completed a safety review for its Phase 1 trial of GTB-3650, which targets relapsed or refractory blood cancers. The company is advancing to Cohort 4, with plans to initiate dosing soon. Additionally, GTB-5550 is in development for various solid tumors, with human trials expected to begin in late 2025.

Natural Killer Cell therapies in Immunotherapy market worth $254B revolutionized by CAR-NK cells, engineered to evade immune system, enhance cancer destruction.

A news commentary by Equity Insider reported on behalf of GT Biopharma, Inc. stated that MIT and Harvard researchers have developed specialized CAR-NK cells that are designed to evade detection by the immune system and demonstrate enhanced efficacy in combating cancer. This breakthrough was achieved on October 17, 2025, in Vancouver, BC. The engineered CAR-NK cells show promise in significantly improving cancer treatment due to their ability to effectively target and destroy cancer cells.

09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

MIT and Harvard scientists have engineered CAR-NK cells that evade the immune system, enhancing cancer treatment efficacy. The global cancer immunotherapy market is projected to grow from $105.7 billion in 2024 to $254.6 billion by 2033. GT Biopharma, Inc. is advancing its Phase 1 trial of GTB-3650, targeting relapsed blood cancers, with promising early results in immune activation. The company is also developing GTB-5550 for solid tumors, with plans to file for human trials in late 2025. CEO Michael Breen expressed optimism about the trial's progress and future data releases.

09:00 ET Precision Oncology Approaches Drive $312B Market Transformation

The precision oncology market is rapidly evolving, projected to grow from $133 billion in 2025 to over $312 billion by 2034, driven by advancements in biomarker-driven drug development and early detection diagnostics. Companies like GT Biopharma, Inc. are at the forefront, with promising results from their Phase 1 trial of GTB-3650 for treating difficult blood cancers. The trial has shown encouraging immune activation without significant side effects, indicating potential for effective cancer therapies. GT Biopharma plans to release more data in early 2026, highlighting their innovative approaches in oncology.